Brio Financial Group congratulates our client, Pelthos Therapeutics Inc. (hashtagNYSE American: hashtagPTHS), on its acquisition of Xeglyze® (abametapir), an FDA approved prescription topical treatment for head lice, from Hatchtech Pty Ltd., for $1.8 million.
Xeglyze is indicated for the topical treatment of head lice infestation in patients 6 months of age and older, and was originally approved by the FDA in July 2020.
This acquisition expands Pelthos’ commercial portfolio with a complementary, differentiated product and provides Pelthos with the ability to commercialize Xeglyze worldwide, with zero future milestone, royalty, or other payments owed to Hatchtech.
Congratulations to Scott Plesha, CEO and Frank Knuettel II, CFO of Pelthos Therapeutics, and the full Pelthos team on this important milestone.